A type II cannabis extract and a 1:1 blend of &#916;(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.

Benredjem, Besma; Pineyro, Graciela

A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.

Benredjem, Besma; Pineyro, Graciela.

Afiliação

Benredjem B; Département de Pharmacologie, Université de Montréal, Montreal, QC, Canada.
Pineyro G; CHU Sainte-Justine Research Center, Montreal, QC, Canada.

Front Pharmacol ; 14: 1235255, 2023.

Article em En | MEDLINE | ID: mdl-37745077